Callan Family Office LLC Purchases New Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Callan Family Office LLC purchased a new stake in shares of Elanco Animal Health Incorporated (NYSE:ELAN) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund purchased 36,720 shares of the company’s stock, valued at approximately $445,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in ELAN. AM Squared Ltd purchased a new position in Elanco Animal Health in the third quarter valued at about $34,000. Wilmington Savings Fund Society FSB bought a new stake in shares of Elanco Animal Health in the 3rd quarter worth approximately $35,000. Farther Finance Advisors LLC raised its holdings in shares of Elanco Animal Health by 158.7% in the 3rd quarter. Farther Finance Advisors LLC now owns 3,332 shares of the company’s stock worth $49,000 after purchasing an additional 2,044 shares during the period. Venturi Wealth Management LLC lifted its stake in Elanco Animal Health by 89.9% in the third quarter. Venturi Wealth Management LLC now owns 3,382 shares of the company’s stock valued at $50,000 after purchasing an additional 1,601 shares during the last quarter. Finally, Jones Financial Companies Lllp grew its holdings in Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock valued at $51,000 after purchasing an additional 2,059 shares during the period. 97.48% of the stock is owned by institutional investors.

Elanco Animal Health Trading Up 2.7 %

NYSE ELAN opened at $11.12 on Monday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. Elanco Animal Health Incorporated has a fifty-two week low of $10.20 and a fifty-two week high of $18.80. The stock has a market cap of $5.50 billion, a P/E ratio of 27.80, a price-to-earnings-growth ratio of 2.50 and a beta of 1.44. The stock has a 50 day simple moving average of $11.62 and a two-hundred day simple moving average of $12.89.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Tuesday, February 25th. The company reported $0.14 EPS for the quarter, missing the consensus estimate of $0.15 by ($0.01). The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The firm’s revenue for the quarter was down 1.4% compared to the same quarter last year. During the same quarter last year, the company posted $0.08 earnings per share. On average, analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Analyst Ratings Changes

ELAN has been the topic of several recent research reports. Barclays dropped their price objective on shares of Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a report on Wednesday, February 26th. Leerink Partners initiated coverage on shares of Elanco Animal Health in a research note on Monday, December 2nd. They set a “market perform” rating and a $14.00 price target on the stock. UBS Group reduced their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Stifel Nicolaus lowered their target price on shares of Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Friday, February 21st. Finally, Morgan Stanley cut their price target on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating for the company in a report on Wednesday, February 26th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $15.17.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.